Technical Analysis for IMVIQ - Imv Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Doji - Bullish? | Reversal | 14.29% | |
| Gapped Down | Weakness | 14.29% | |
| Hot IPO Pullback | Bullish Swing Setup | -20.00% | |
| Gapped Down | Weakness | -20.00% | |
| Gapped Up | Strength | 0.00% | |
| Shooting Star Candlestick | Bearish | -20.40% | |
| Doji - Bearish? | Reversal | -20.40% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
| Gap Up Partially Closed | 2 days ago |
| Gap Up Closed | 2 days ago |
| Gapped Up (Partial) | 2 days ago |
Get a Trading Sidekick!
Imv Inc Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Classification
Keywords: Medicine Medical Specialties Cancer Clinical Medicine Infectious Diseases Breast Cancer Oncology Immunotherapy Cancer Immunotherapy Ovarian Cancer Bladder Cancer Covid 19 Diffuse Large B Cell Lymphoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.46 |
| 52 Week Low | 0.03 |
| Average Volume | 57,602 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 0.1001 |
| Average True Range | 0.1757 |
| RSI (14) | 51.22 |
| ADX | 0.0 |
| +DI | 14.2276 |
| -DI | 3.6585 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | -0.0111 |
| MACD Signal Line | -0.0041 |
| MACD Histogram | -0.0069 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.2600 | ||||
| Resistance 3 (R3) | 0.2800 | 0.2400 | 0.2300 | ||
| Resistance 2 (R2) | 0.2400 | 0.1942 | 0.2300 | 0.2200 | |
| Resistance 1 (R1) | 0.1600 | 0.1658 | 0.1400 | 0.1400 | 0.2100 |
| Pivot Point | 0.1200 | 0.1200 | 0.1100 | 0.1100 | 0.1200 |
| Support 1 (S1) | 0.0400 | 0.0742 | 0.0200 | 0.0200 | -0.0500 |
| Support 2 (S2) | 0.0000 | 0.0458 | -0.0100 | -0.0600 | |
| Support 3 (S3) | -0.0800 | 0.0000 | -0.0700 | ||
| Support 4 (S4) | -0.1000 |
